הכנסה תפעולית לפני ניכוי פחת: Silo Pharma Inc. (SILO)

The development of Silo Pharma, Inc. (SILO) is based on clinical trials of psychedelics for the treatment of depression and fibromyalgia while maintaining a stable balance. The company's EBITDA demonstrates current cash flow resilience, with the metric standing at 0.00. The firm is implementing microdosing to combat pain without inducing hallucinations, and is also researching the effects of psilocybin on PTSD and Alzheimer's disease.

For biopharmaceutical innovator Silo Pharma, Inc. (SILO), which is developing depression therapies, this indicator captures the actual volume of cash generated, excluding non-cash expenses and the impact of credit policy. The metric allows for an assessment of operational cost management efficiency and cash flow predictability, which is critical for evaluating the sustainability of R&D projects by analyzing the absolute EBITDA trend for hidden costs.